/ /

Vanessa Caceres
Novel contact lens helps treat corneal edema after cataract surgery
A new contact lens to treat corneal edema after cataract surgery had favorable results in a group of 33 patients with corneal edema after extracapsular cataract extraction and IOL implantation and refractive lens exchange.
Integrin peptide yields positive outcomes for VMA, VMT in phase II trial
A new possible therapy for vitreomacular adhesion and vitreomacular traction had positive results in a phase II trial.
Tackling presbyopia with an inlay
Tackling presbyopia with an inlay
An investigational corneal inlay for presbyopia called the Raindrop had good near visual acuity results and patient satisfaction in a group of active patients.
MIGS stent yields good IOP control as stand-alone treatment
Microstent implantation had favorable and safe results in a group of patients with open-angle glaucoma in the DUETTE trial.
Autoimmune retinopathy: While uncommon, viable option for unexplained vision loss
Ophthalmologists should suspect autoimmune retinopathy if a patient presents with an unexplained visual loss.
No capsule support? Anterior chamber versus posterior chamber IOL
Take-home message: When considering IOL implantation options when there is a lack of capsular support, cataract surgeons should use the approach with which they are most comfortable. They should also continue to learn about new available techniques.
Integrin peptide trials continue for wet AMD, DME, other pathologies
The first drug in the new class integrin peptide therapy continues to show continued efficacy and safety in various clinical trials.
Dexamethasone for DME shows stronger results compared with sham group
In this article Dr Anat Lowenstein explains that the benefits of treatment with a dexamethasone intravitreal implant for DME were observed across a variety of demographic characteristics.
Prior vitrectomy does not affect DME therapy with ranibizumab, laser
Analysis of eyes with and without prior vitrectomy from DRCR Protocol I showed similar results when treated with ranibizumab with prompt or deferred laser.
Taking on tacrolimus to treat vernal keratoconjunctivitis
Tacrolimus 0.01% was effective for the treatment of vernal keratoconjunctivitis in a study with 62 patients.


View Results